<SEC-DOCUMENT>0001183740-23-000134.txt : 20231226
<SEC-HEADER>0001183740-23-000134.hdr.sgml : 20231226
<ACCEPTANCE-DATETIME>20231222182657
ACCESSION NUMBER:		0001183740-23-000134
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231222
FILED AS OF DATE:		20231226
DATE AS OF CHANGE:		20231222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRIGHT MINDS BIOSCIENCES INC.
		CENTRAL INDEX KEY:			0001827401
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40997
		FILM NUMBER:		231511065

	BUSINESS ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
		BUSINESS PHONE:		6474072515

	MAIL ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k20231222.htm
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2021 [PPXY7CNC5JSVVFDLV1AJ]. www.edgarsuite.com -->
<HEAD>
<TITLE>UNITED STATES</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:64.8pt;width:482.4pt><P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>UNITED STATES</B><BR><B>SECURITIES AND EXCHANGE COMMISSION</B><BR><B>Washington, D.C. &nbsp;20549</B></P>
<P align=center style='font:14pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>FORM 6-K</B></P>
<P align=center style='font:12pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>For the month of <B>December 2023</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Commission File No. <B>001-40997</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><FONT style='font-size:13pt;border-bottom:1px solid #000000'><B>BRIGHT MINDS BIOSCIENCES INC.</B></FONT><BR>(Translation of registrant's name into English)</P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>19 Vestry Street,</B><BR><FONT style='border-bottom:1px solid #000000'><B>New York, NY &nbsp;10013</B></FONT><BR>(Address of principal executive office)</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F</P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>Form 20-F</B>&#160;&#160;<B>[ X ]</B> &nbsp;Form 40-F<B>&#160;&#160;[ &nbsp;]</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) &#160;[ &nbsp;]</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) &#160;[ &nbsp;]</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P align=center style='font:11pt Times New Roman;margin:0;background-color:#FFFFFF'><A name=_DV_M0 /><B>SUBMITTED HEREWITH</B></P>
<TABLE align=center style=border-collapse:collapse;width:475.45pt><TR><TD valign=top style=width:56.95pt><P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:5.4pt;color:#000000'><FONT style='border-bottom:1px solid #000000'><B>Exhibits</B></FONT></P>
</TD><TD valign=top style=width:418.5pt><P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:4.5pt;margin-right:7.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:12.15pt><TD valign=top style=width:56.95pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-left:5.4pt;color:#000000'>99.1</P>
</TD><TD valign=top style=width:418.5pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-left:2.6pt;margin-right:1.95pt;color:#000000'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=ex991-20231222.htm style=text-decoration:none>News Release dated </A><A href=ex991-20231222.htm style=text-decoration:none>December 22</A><A href=ex991-20231222.htm style=text-decoration:none>, 2023</A></FONT></P>
</TD></TR>
</TABLE>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
</DIV>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>SIGNATURE</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:216pt'><B>BRIGHT MINDS BIOSCIENCES INC.</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:216pt'><BR><FONT style='border-bottom:1px solid #000000'><I>&#8220;Ryan Cheung&#8221;</I></FONT><KBD style='display:inline-block;width:139.3pt;border-bottom:1px solid #000000'>&nbsp;</KBD> <BR>Ryan Cheung<BR>Chief Financial Officer&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Date:  December 22, 2023</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-20231222.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2021 [PPXY7CNC5JSVVFDLV1AJ]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000'><IMG src=ex99120231222_1.jpg width=113 height=88 alt=image1.png title=image1.png>&nbsp;</P>
<P align=center style='font:14pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'><A name=_DV_M113 /><A name=_DV_M114 /><A name=_DV_M115 /><A name=_DV_M119 /><B>Bright Minds Announces Closing of Non-Brokered Private Placement Fully Subscribed by Management</B></P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>Vancouver, British Columbia, December 22, 2023 &#8211;&nbsp;Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (&#8220;<B>Bright Minds</B>&#8221; or the &#8220;<B>Company</B>&#8221;), a leading biotechnology company specializing in the development of novel treatments for neuropsychiatric disorders, epilepsy, and pain, is pleased to announce that, further to its news release dated December 6, 2023, it has closed a fully management-subscribed, non-brokered private placement. The private placement consisted of 661,765 units of the Company (the &#8220;<B>Units</B>&#8221;) at a price of $1.36 per Unit for aggregate gross proceeds of $900,000 (the &#8220;<B>Offering</B>&#8221;). The proceeds from the Offering are intended to further the progress of Bright Minds&#8217; Phase 2 Clinical Trial for BMB-101 in a pediatric epilepsy indication. </P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>Each Unit consists of one common share in the capital of Bright Minds (a &#8220;<B>Share</B>&#8221;) and one Share purchase warrant (a &#8220;<B>Warrant</B>&#8221;). Each Warrant grants the holder the right to acquire one Share (a &#8220;<B>Warrant Share</B>&#8221;) at a price of $1.70 per Warrant Share for a period of 60 months from the date of issuance. </P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>The Offering was conducted under the listed issuer financing exemption as per Part 5A of National Instrument 45-106 - <I>Prospectus Exemptions</I>. As a result, the securities issued are not subject to a hold period under the prevailing Canadian securities laws. </P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>Ian McDonald, the Chief Executive Officer and a Director of Bright Minds, subscribed for 100% of the Units in this Offering. Mr. McDonald&#8217;s participation was intended to assist the Company with funding the Phase 2 Clinical Trial for BMB-101 without incurring expenses related to a broad offering of securities, as the Company&#8217;s other resources are currently devoted to ongoing research projects and general working capital needs.</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&#8220;With the closing of this placement, we're closer to transforming pediatric epilepsy care with BMB-101, a testament to our commitment to deliver an innovative epilepsy treatment for children who have limited options,&#8221; stated Ian McDonald, CEO of Bright Minds.</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>Mr. McDonald&#8217;s participation in the Offering constitutes a &#8220;related party transaction&#8221; as defined in Multilateral Instrument 61-101 - <I>Protection of Minority Securityholders in Special Transactions</I> (&#8220;<B>MI 61-101</B>&#8221;). The Company is relying on the exemption from valuation requirement and minority approval pursuant to subsection 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, for Mr. McDonald&#8217;s participation in the Offering, as the value of the Units subscribed for do not represent more than 25% of the Company&#8217;s market capitalization, as determined in accordance with MI 61-101.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9.35pt;margin-right:-4.3pt'><B>About Bright Minds</B></P>
<P align=justify style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9.35pt;margin-right:-4.3pt'>Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds&#8217; drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first- generation compounds, such as fenfluramine, psilocybin, LSD, and ibogaine.</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'><B>Investor Contacts:</B></P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>Ian McDonald</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>CEO and Director</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#0000FF'><FONT style=color:#000000>E: </FONT><FONT style='border-bottom:1px solid #0000FF'>ian@brightmindsbio.com</FONT></P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#0000FF'>&nbsp;</P>
<P align=justify style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'><I>This news release includes certain statements that may be deemed &#8220;forward-looking statements&#8221;. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;potential&#8221; and similar expressions, or that events or conditions &#8220;will&#8221;, &#8220;would&#8221;, &#8220;may&#8221;, &#8220;could&#8221; or &#8220;should&#8221; occur. Forward-looking statements in this news release include, without limitation, statements related to the anticipated use of proceeds from the Offering. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company&#8217;s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.</I></P>
<P align=justify style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'><I>Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release.</I></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99120231222_1.jpg
<TEXT>
begin 644 ex99120231222_1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< '<# 2(  A$! Q$!_\0
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MGZW=36T8N!*B(5&W[Q)]ZTK/PYX;M_BVJ6VFV,5Q/HKRWEFD:LD;^;'M;&,
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M2@$KSQ[9KSRM3Q')-/XEU.YGM)[1[BZDF\B=2KH&8L 0?K670 4444 %%%%
M'1^!!;-XTT]+I@(W+HI9MHWLC!,GTW$=C]#7;:UIMG8^%M;N)["WLXW@2*!1
M"8I6E\P$9(C4,OR@XSQC)'IY-6EJNNWNL) EWY.(0<&*%4+L0 6; ^9B%7D^
ME ';? K_ )*OI_\ UQG_ /1;5[D8O!O_  EW_"=;_P#B8"Y_L7RL#/VOS/+S
MC^_MXS_=YKYC\'^*;KP9XD@UNS@AGFA5U"39VG<I!Z$'O0?%=\?%O]O[5W_V
ME_:7V7<WE>;OW=,_AGKB@#VR_/\ QE=8_P#7 ?\ I.U)X*/_ !DOXI_ZXS?^
MA1UY?-\3M2G^(\/C5K&T%[$FP0#=Y9^0IZYZ'UI-)^)VI:1X^U'Q=%8VCW=\
MK*\+[O+7<5)QSG^$=Z /H;PYX>T>^\=-X\T"9!!>6TUK>P8P1,'7+8['Y3D?
M0]Z\]^"MS+9GXAW,+!985$B$C(##SB#BO._"'Q1UOP9J>HW5E'!-#?N9);6;
M<8PY.=RX((/;W'7H*/!?Q-U'P3=:M/9V%G<G4V5I5GW87!8X&"/[YZT >I>'
M-=O?BA\+?%'_  EUK R6,326M\(MF'",V1VRI49QU#8-9WPJ\6:+:?#F71#K
M?_"-ZH]TS#47MU9)#D'[S#:2%P""0<<BN&\6?&#Q)XKTEM)9+33]/? DALT*
M^8,YP223CV&*7PE\6=4\+:$-$DTO3-2TU6+I%<P\@DY/(Z_B"?>@#3^-MAXE
M@U;2KS7=1L]1MIK<I9W-I%Y8< @L67)Y.X'()'/%>5UU/C?Q[JOCN^MYM02"
M""U0I;VUNI"1@XSUY).!^0KEJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
